concept

TAU PATHOLOGY

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about TAU PATHOLOGY: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1214Connections

1Hypotheses

5Analyses

50Outgoing

50Incoming

0Experiments

11Debates

Summary

TAU PATHOLOGY is a concept in neurodegeneration research. Key relationships include: activates, biomarker for, therapeutic target. Associated with ALS, Aging, Als. Connected to 600 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	TAU PATHOLOGY
Key Genes/Proteins	ABCA1, ABI3, ACE, ADAM17, ADORA1, AGING
Related Diseases	aging, Aging, Als, ALS, Alzheimer
Related Pathways	Akt, Alpha-Synuclein

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

Cyclica

company · 2516 words

→

Pathway Diagram

graph TD
    TAU_PATHOLOGY["TAU PATHOLOGY"]
    TAU_PATHOLOGY -->|"activates"| neurodegeneration["neurodegeneration"]
    TAU_PATHOLOGY -->|"causes"| synapse_loss["synapse loss"]
    TAU_PATHOLOGY -->|"causes"| Alzheimer_s_disease["Alzheimer's disease"]
    TAU_PATHOLOGY -->|"activates"| inflammatory_responses["inflammatory responses"]
    TAU_PATHOLOGY -->|"activates"| neuroinflammation["neuroinflammation"]
    TAU_PATHOLOGY -.protects against.-> Alzheimer["Alzheimer"]
    autophagy_dysfunction["autophagy dysfunction"] -->|"activates"| TAU_PATHOLOGY
    necroptosis["necroptosis"] -->|"activates"| TAU_PATHOLOGY
    MHC_I["MHC-I"] -->|"activates"| TAU_PATHOLOGY
    APOE["APOE"] -->|"regulates"| TAU_PATHOLOGY
    ApoE4["ApoE4"] -->|"contributes to"| TAU_PATHOLOGY
    TREM2["TREM2"] -->|"regulates"| TAU_PATHOLOGY
    APOE3["APOE3"] -->|"regulates"| TAU_PATHOLOGY

Outgoing (658)

Target	Relation	Type	Str
Alzheimer	biomarker_for	disease	1.00
Neurodegeneration	associated_with	disease	1.00
Aging	associated_with	disease	1.00
ALZHEIMER'S DISEASE	therapeutic_target	gene	1.00
neurodegeneration	activates	process	1.00
Als	biomarker_for	disease	1.00
Alzheimer	regulates	disease	1.00
Alzheimer	activates	disease	1.00
Neurodegeneration	activates	disease	1.00
Als	associated_with	disease	1.00
Alzheimer	associated_with	disease	1.00
Alzheimer	therapeutic_target	disease	1.00
ALZHEIMER'S DISEASE	activates	gene	1.00
MICROGLIA	activates	gene	1.00
ALZHEIMER'S DISEASE	associated_with	gene	1.00
Aging	therapeutic_target	disease	0.95
Neurodegeneration	regulates	disease	0.95
Als	therapeutic_target	disease	0.95
Inflammation	regulates	disease	0.95
Als	activates	disease	0.95
Neuroinflammation	regulates	disease	0.95
Alzheimer's Disease	associated_with	disease	0.95
Neurodegeneration	inhibits	disease	0.95
Alzheimer	protects_against	disease	0.95
Alzheimer'S Disease	biomarker_for	disease	0.95
Aging	activates	disease	0.95
Behavior Variant Frontotemporal Dementia	involved_in	disease	0.92
Alzheimer'S	biomarker_for	disease	0.92
Neurodegeneration	causes	process	0.90
Alzheimer Disease	involved_in	disease	0.90
Neuronal And Synaptic Loss	causes	phenotype	0.90
Schaffer collaterals	spreads_along	pathway	0.90
Cognitive Decline	causes	phenotype	0.90
Necroptosis	associated_with	process	0.90
mitochondrial dysfunction	causes	process	0.90
A1R	upregulates	protein	0.90
Alzheimer's Disease	drives	disease	0.90
GFAP	biomarker_for	gene	0.90
ALZHEIMER'S DISEASE	biomarker_for	gene	0.90
Inflammation	therapeutic_target	disease	0.85
Tauopathy	therapeutic_target	disease	0.85
Microgliosis	causes	process	0.85
Alzheimer's Disease	biomarker_for	disease	0.85
cortical gray matter connectivity	mediates	phenotype	0.85
Alzheimer	inhibits	disease	0.85
Dementia	associated_with	disease	0.85
Alzheimer'S Disease	contributes_to	disease	0.85
Neuroinflammation	associated_with	disease	0.85
Inflammation	associated_with	process	0.85
Inflammation	associated_with	disease	0.85

Incoming (556)

Source	Relation	Type	Str
AMYLOID	associated_with	gene	1.00
NEURODEGENERATION	associated_with	gene	1.00
TAU	associated_with	gene	1.00
ALZHEIMER	associated_with	gene	1.00
ALZHEIMER	therapeutic_target	gene	1.00
TAU	inhibits	gene	1.00
ALZHEIMER	activates	gene	1.00
TAU	activates	gene	1.00
AMYLOID	activates	gene	1.00
TAU	regulates	gene	1.00
Phosphorylated Tau 217	biomarker_for	biomarker	0.96
Electroacupuncture	suppresses	drug	0.95
Lxr Agonist	suppresses	drug	0.95
mAb2A7	associated_with	drug	0.95
APOE4	associated_with	protein	0.95
Plasma Ev Tau 3R/4R Ratio	biomarker_for	biomarker	0.94
Tau PET	biomarker_for	biomarker	0.93
P-Tau217	biomarker_for	biomarker	0.93
Neuroinflammation	involved_in	process	0.92
PSEN1	causes	gene	0.92
Tau Positron Emission Tomography	biomarker_for	biomarker	0.91
APOE	associated_with	gene	0.90
Intermediate Filaments	interacts_with	protein	0.90
29895964	correlates better with	paper	0.90
Oligodendrocytes	interacts_with	cell_type	0.90
40264187	reduced	paper	0.90
Mab2A7	associated_with	drug	0.90
Necroptosis	correlates_with	process	0.90
Proteasomal Degradation	regulates	pathway	0.90
APOE4	upregulates	gene	0.90
proteasomal degradation	involved_in	process	0.90
34326423	is associated with	paper	0.90
APOE-R136S	protects_against	protein	0.90
34326423	is associated with	paper	0.90
Apoe4	associated_with	protein	0.90
36153607	progresses preferentially between	paper	0.90
Aβ accumulation	causes	biomarker	0.90
31285742	appears in	paper	0.90
LDLR	inhibits	gene	0.90
autosomal dominant Alzheimer's Disease	causes	disease	0.90
APOE4	promotes	gene	0.90
ABCA1	suppresses	gene	0.90
RING-Bait	associated_with	drug	0.90
BAG3	protects_against	protein	0.90
APOE	mediates	gene	0.90
Dazucorilant	treats	drug	0.90
NEURODEGENERATION	inhibits	gene	0.90
AMYLOID	biomarker_for	gene	0.90
ALZHEIMER	biomarker_for	gene	0.90
NEURODEGENERATION	activates	gene	0.90

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
CSF p-tau217 Normalization Reflects Amyloid-Driven Tau Patho	0.586	neurodegeneration	-

Mentioning Analyses (5)

Scientific analyses that reference this entity

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (11)

Multi-agent debates referencing this entity

Related Research

Hypotheses and analyses mentioning TAU PATHOLOGY in their description or question text

No additional research found

TAU PATHOLOGY

Understanding Entity Pages

Summary

Wiki Pages (1)

Cyclica

Pathway Diagram

Outgoing (658)

Incoming (556)

Targeting Hypotheses (1)

Mentioning Analyses (5)

Clinical Trial Landscaping for Alzheimer's Disease Therapeutics

Multi-modal Biomarker Panel Design for Early AD Detection

Spatial Transcriptomics Analysis of Alzheimer's Disease Brain Regions

Lysosomal dysfunction and cathepsin leakage in Alzheimer disease progression

Circuit-level neural dynamics in neurodegeneration

Experiments (0)

Related Papers (0)

Debates (11)

Hypothesis debate: Closed-loop optogenetic targeting PV interneurons to restore

Hypothesis debate: Closed-loop transcranial focused ultrasound targeting EC-II S

Hypothesis debate: Closed-loop transcranial focused ultrasound with 40Hz gamma e

Lysosomal membrane permeabilization releasing cathepsins triggers NLRP3 inflamma

How does spatial gene expression in the hippocampus and entorhinal cortex distin

Can a multi-modal biomarker panel combining plasma proteins, neuroimaging featur

What is the current clinical trial landscape for AD therapeutics, and which mech

Is the amyloid concentration in AD clinical trials rational given lecanemab's ap

Should clinical practice adopt multi-modal biomarker panels now, or wait for sin

Do spatial transcriptomic neighborhoods provide sufficient discriminative power

Related Research